BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 26504363)

  • 1. A Survey of Attitudes towards the Clinical Application of Systemic Inflammation Based Prognostic Scores in Cancer.
    Watt DG; Roxburgh CS; White M; Chan JZ; Horgan PG; McMillan DC
    Mediators Inflamm; 2015; 2015():842070. PubMed ID: 26504363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of the systematic inflammation-based Glasgow Prognostic Score in patients with gastric cancer: a literature review.
    Gao Y; Huang D
    J Cancer Res Ther; 2014; 10(4):799-804. PubMed ID: 25579511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.
    McMillan DC
    Cancer Treat Rev; 2013 Aug; 39(5):534-40. PubMed ID: 22995477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study.
    Proctor MJ; Morrison DS; Talwar D; Balmer SM; Fletcher CD; O'Reilly DS; Foulis AK; Horgan PG; McMillan DC
    Eur J Cancer; 2011 Nov; 47(17):2633-41. PubMed ID: 21724383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study.
    Shafique K; Proctor MJ; McMillan DC; Qureshi K; Leung H; Morrison DS
    Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):195-201. PubMed ID: 22343838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prevalence of cancer associated systemic inflammation: Implications of prognostic studies using the Glasgow Prognostic Score.
    Dolan RD; McMillan DC
    Crit Rev Oncol Hematol; 2020 Jun; 150():102962. PubMed ID: 32344318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An exploratory study examining the relationship between performance status and systemic inflammation frameworks and cytokine profiles in patients with advanced cancer.
    Dolan RD; Laird BJA; Klepstad P; Kaasa S; Horgan PG; Paulsen Ø; McMillan DC
    Medicine (Baltimore); 2019 Sep; 98(37):e17019. PubMed ID: 31517821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostication in advanced cancer: a study examining an inflammation-based score.
    Partridge M; Fallon M; Bray C; McMillan D; Brown D; Laird B
    J Pain Symptom Manage; 2012 Aug; 44(2):161-7. PubMed ID: 22732417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
    Leung EY; Scott HR; McMillan DC
    J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of scores based on malnutrition or systemic inflammatory response in patients with metastatic or recurrent gastric cancer.
    Sachlova M; Majek O; Tucek S
    Nutr Cancer; 2014; 66(8):1362-70. PubMed ID: 25356861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system.
    Laird BJ; Kaasa S; McMillan DC; Fallon MT; Hjermstad MJ; Fayers P; Klepstad P
    Clin Cancer Res; 2013 Oct; 19(19):5456-64. PubMed ID: 23938289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The application of the Palliative Prognostic Index, charlson comorbidity index, and Glasgow Prognostic Score in predicting the life expectancy of patients with hematologic malignancies under palliative care.
    Chou WC; Kao CY; Wang PN; Chang H; Wang HM; Chang PH; Yeh KY; Hung YS
    BMC Palliat Care; 2015 Apr; 14():18. PubMed ID: 25924723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
    Martin HL; Ohara K; Kiberu A; Van Hagen T; Davidson A; Khattak MA
    Intern Med J; 2014 Jul; 44(7):676-82. PubMed ID: 24750233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inflammation-based modified Glasgow Prognostic Score in patients with vulvar cancer.
    Hefler-Frischmuth K; Seebacher V; Polterauer S; Tempfer C; Reinthaller A; Hefler L
    Eur J Obstet Gynecol Reprod Biol; 2010 Mar; 149(1):102-5. PubMed ID: 20080329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
    Linton A; Pond G; Clarke S; Vardy J; Galsky M; Sonpavde G
    Clin Genitourin Cancer; 2013 Dec; 11(4):423-30. PubMed ID: 23816526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer.
    Roxburgh CS; Salmond JM; Horgan PG; Oien KA; McMillan DC
    Ann Surg; 2009 May; 249(5):788-93. PubMed ID: 19387324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer.
    Crumley AB; Stuart RC; McKernan M; McDonald AC; McMillan DC
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 2):e325-9. PubMed ID: 17645468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of the systemic inflammation-based Glasgow prognostic score: a Glasgow Inflammation Outcome Study.
    Proctor MJ; Horgan PG; Talwar D; Fletcher CD; Morrison DS; McMillan DC
    Cancer; 2013 Jun; 119(12):2325-32. PubMed ID: 23575969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer.
    McMillan DC
    Proc Nutr Soc; 2008 Aug; 67(3):257-62. PubMed ID: 18452641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer.
    Inoue Y; Iwata T; Okugawa Y; Kawamoto A; Hiro J; Toiyama Y; Tanaka K; Uchida K; Mohri Y; Miki C; Kusunoki M
    Oncology; 2013; 84(2):100-7. PubMed ID: 23147449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.